c-Met inhibitors

[1]  Keith T Flaherty,et al.  Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Syed Muhammad Saad Anwer,et al.  Clouds with silver lining: Defining conditions that serve as blessings in disguise , 2012 .

[3]  E. Brusina,et al.  Infectious Agents and Cancer , 2012, Springer Netherlands.

[4]  M. Ashwell,et al.  Discovery of a Novel Mode of Protein Kinase Inhibition Characterized by the Mechanism of Inhibition of Human Mesenchymal-epithelial Transition Factor (c-Met) Protein Autophosphorylation by ARQ 197 , 2011, The Journal of Biological Chemistry.

[5]  J. Porter.  Small molecule c-Met kinase inhibitors: a review of recent patents , 2010, Expert opinion on therapeutic patents.

[6]  D. Fisher,et al.  Identification of the receptor tyrosine kinase c-Met and its ligand, hepatocyte growth factor, as therapeutic targets in clear cell sarcoma. , 2010, Cancer research.

[7]  R. Salgia,et al.  The MET axis as a therapeutic target. , 2009, Update on cancer therapeutics.

[8]  S. Bellon,et al.  From concept to reality: the long road to c-Met and RON receptor tyrosine kinase inhibitors for the treatment of cancer. , 2009, Anti-cancer agents in medicinal chemistry.

[9]  L. Trusolino,et al.  Drug development of MET inhibitors: targeting oncogene addiction and expedience , 2008, Nature Reviews Drug Discovery.

[10]  J. Christensen,et al.  c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. , 2005, Cancer letters.

[11]  F. Martínez-Murillo,et al.  Regulation of c-Met-dependent gene expression by PTEN , 2004, Oncogene.

[12]  Kitty Tang,et al.  ERK and MMPs sequentially regulate distinct stages of epithelial tubule development. , 2004, Developmental cell.

[13]  A. Howlett,et al.  Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. , 2003, Molecular cancer therapeutics.

[14]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[15]  A. Bell,et al.  Hepatocyte Growth Factor Induces Wnt-independent Nuclear Translocation of β-Catenin after Met-β-Catenin Dissociation in Hepatocytes , 2002 .

[16]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[17]  P. Comoglio,et al.  Somatic mutations of the MET oncogene are selected during metastatic spread of human HNSC carcinomas , 2000, Oncogene.

[18]  L. Schmidt,et al.  Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. , 1999, Cancer research.

[19]  S. Scherer,et al.  Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas , 1997, Nature Genetics.

[20]  D. Birnbaum,et al.  Localization of the 5' end of the MCF2 oncogene to human chromosome 15q15----q23. , 1992, Cytogenetics and cell genetics.

[21]  L. Cantley,et al.  The tyrosine-phosphorylated hepatocyte growth factor/scatter factor receptor associates with phosphatidylinositol 3-kinase. , 1991, The Journal of biological chemistry.

[22]  N. Fausto.  Hepatocyte growth factor receptor and the c-met oncogene Bottaro DP, Rubin JS, Faletto DL, Chan AM-L, Kmiecik TE, Vande Woude GF, Aaronson SA. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802?804 , 1991 .

[23]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[24]  P. Scherle,et al.  Developing c-MET pathway inhibitors for cancer therapy: progress and challenges. , 2010, Trends in molecular medicine.

[25]  S. Miknyoczki,et al.  Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. , 2010, Anti-cancer agents in medicinal chemistry.

[26]  A. Bell,et al.  Hepatocyte growth factor induces Wnt-independent nuclear translocation of beta-catenin after Met-beta-catenin dissociation in hepatocytes. , 2002, Cancer research.